Form 4: Recursion Pharma Director Li Acquires Shares

Recursion Pharmaceuticals Director Dean Y. Li acquired 1,961 shares of Class A Common Stock as part of the company's established outside director compensation policy.

Summary

• Dean Y. Li, a Director of Recursion Pharmaceuticals, Inc. (RXRX), acquired 1,961 shares of Class A Common Stock.
• The transaction occurred on October 1, 2025.
• These shares were issued at a price of $0, consistent with the Issuer's Outside Director Compensation Policy.
• Following this transaction, Dean Y. Li directly beneficially owns 1,238,528 shares.
• Indirect beneficial ownership includes 1,422,048 shares via the Dean Y. Li Revocable Trust, 136,981 shares via the Dean Y. Li GRAT, and 421,000 shares via the Dean Y. Li 2021 Family Trust.

Sentiment

Score: 6

Explanation: Slightly positive as it indicates a director's continued equity stake and routine corporate governance, but it's a standard compensation event rather than a significant new investment.

Positives

• Director Dean Y. Li increased his beneficial ownership in the company, demonstrating continued commitment.
• The transaction is part of a standard, established Outside Director Compensation Policy, indicating routine corporate governance.

Future Outlook

This filing does not provide any forward-looking statements or guidance.

Industry Context

The acquisition of shares by a director as part of an established compensation policy is a common practice across publicly traded companies, aligning director interests with shareholder value.

Comparison to Industry Standards

• Director compensation policies, often including equity grants, are standard practice in the biotechnology and pharmaceutical industry, similar to companies like Regeneron Pharmaceuticals or Vertex Pharmaceuticals, which use equity to incentivize and retain key leadership. The $0 price indicates a grant, which is typical for such compensation.

Stakeholder Impact

• Shareholders may view the director's increased equity stake as a positive sign of alignment with shareholder interests and confidence in the company's future.

Key Dates

Recommendation

This Form 4 filing details a routine compensation grant to a director and does not provide new information that would significantly alter the investment thesis for Recursion Pharmaceuticals. While an increase in insider ownership is generally positive, this specific transaction is a standard part of director compensation rather than a discretionary open-market purchase, thus warranting a 'hold' recommendation based solely on this filing.

Keywords

Recursion Pharmaceuticals, RXRX, Dean Y. Li, Director Compensation, Insider Transaction, Form 4, Stock Acquisition, Beneficial Ownership